An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes

Myocardial infarction and stroke are two of the leading causes of death and disability worldwide [1,2]. Using a combination of aspirin and a platelet P2Y12 antagonist, several large clinical trials have definitively demonstrated the efficacy of dual antiplatelet therapies in preventing myocardial infarction, stroke or death in patients with acute coronary syndromes [3–8]. Dual antiplatelet therapy with aspirin and a thienopyridine-based P2Y12 antagonist (clopidogrel or prasugrel) has now become the standard of care of patients with acute coronary syndromes.
Source: Thrombosis Research - Category: Hematology Authors: Source Type: research